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Abstract
Contrary to the widespread belief that severe malaria is mainly caused by Plasmodium
falciparum, malaria caused by Plasmodium vivax infection may also lead to severe clinical
manifestations including a plethora of renal, pulmonary, hematologic, neurologic, and
multiorgan dysfunction. Anemia and thrombocytopenia are considered as two major
important markers of severity during the clinical course of severe P. vivax malaria. In
highly endemic areas of P. vivax transmission, early diagnosis is crucial in preventing
uncomplicated episodes progressing into severe and complicated clinical forms. In fact,
given the wide geographic distribution of P. vivax, there is a large burden of disease,
often not adequately acknowledged, and resulting from the combined effect of the
large numbers  of  uncomplicated clinical  episodes  and the  increasingly recognized
severe and complicated clinical presentations.
Keywords: Plasmodium vivax, clinical manifestations, diagnosis, treatment, severe,
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1. Introduction
Globally, malaria remains one of the most important infectious diseases affecting humankind
in  terms  of  morbidity  and  mortality  [1,  2].  Plasmodium  vivax  infection  and  Plasmodium
falciparum represent the two most frequent and severe forms of human malaria. Individuals
acquire the infection by the bite of the female Anopheles mosquitoes inoculating microscopic
sporozoites that subsequently reach the liver via the bloodstream. Once in the liver,  the
sporozoites evolve into a schizont that produces merozoites and then releases them into the
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bloodstream coinciding with the onset of the clinical syndrome of malaria [3]. Most impor‐
tantly, most deaths associated with malaria occur in children living in highly endemic settings
[3]. The large social and economic burden attributable to P. vivax in highly endemic settings
results from the elevated number of cases that require medical care in an already impover‐
ished economy diverting cash and family members from work to attend the sick [2,  3].
Uncomplicated P. vivax malaria refers to a febrile illness where there are no hemodynamic
instability, no evidence of major hemolysis, no absence of severe anemia, no evidence of
pulmonary edema or ARDS, and no evidence of severe metabolic acidosis,  renal failure,
hepatic  dysfunction,  focal  neurological  deficits  or  seizures,  or  multi‐organ failure  [4,  5].
Historically, severe malaria is often considered exclusively within the clinical spectrum of
disease caused by infection due to P. falciparum. However, albeit less recognized, infection
due to P. vivax can also lead to clinically severe manifestations and complications including
(a) fatal bleeding due to traumatic or spontaneous rupture of an enlarged spleen, (b) seizures,
(c) shock, (d) hepatitis with cholestasis, (e) renal failure, (f) severe anemia and thrombocyto‐
penia,  (g)  respiratory  distress  and acute  lung injury  (ALI),  (h)  miscarriage  and preterm
delivery, and (h) multi‐organ failure [6]. Of all these complications, the most significant source
of morbidity is by far the occurrence of severe anemia and its consequences. Furthermore, in
many geographic settings, coinfection of P. vivax and P. falciparum may occur in the same host,
and this can be associated with severe clinical manifestations. Therefore, identifying coinfec‐
tion in settings where there is co‐circulation of both Plasmodium spp., the peripheral blood
smear is of utmost clinical importance in the early course of a febrile illness in which malaria
is a consideration [7]. P. vivax malaria was originally described clinically as “benign tertian
malaria”; however, this is a misleading concept because P. vivax is not a benign disease. In
fact,  it  is  increasingly recognized as a major cause of morbidity and mortality in highly
endemic settings.
The clinical spectrum of disease associated with P. vivax infection ranges from asymptomatic
parasitemia and uncomplicated febrile illness to severe and fatal malaria. In this regard, the
host response influences the clinical expression of the disease. Fever may occur with low
parasite densities and may be identified 2–3 days before the parasites are detected in blood,
underscoring the need for serial peripheral blood smear examinations [8]; P. vivax has a lower
pyrogenic threshold (parasitic density required to evoke a fever) compared with P. falcipa‐
rum. Globally, it is estimated that there are more than 80 million episodes of P. vivax malaria
every year resulting in a considerable amount of morbidity and mortality. The prevailing
neglect of the substantial public health impact of P. vivax that occurs in many settings in
comparison with that of P. falciparum relies on its low incidence in Sub‐Saharan Africa as a
result of the evolutionary trait of the Duffy antigen negativity selected among many African
populations [9].
P. vivax causes almost half of all of the 70–390 million clinical cases of malaria each year. In
countries endemic for both major Plasmodium species, P. vivax infection may account for up to
38% of patients hospitalized with malaria. In Indonesian Papua, P. vivax accounted for 24% of
malaria admissions in all age groups, of whom 47% (415/887) are infants [6]. The need for
hospitalization among these cases indicates significant morbidity, and at least moderately
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severe disease. Thus, clinicians should be aware of the spectrum of severe disease and of
potential multi‐organ affection among patients presenting with P. vivax malaria [10–37].
2. Parasitology and epidemiology
Infection due to P. vivax challenges human health in many settings, particularly in Southeast
Asia, in some areas of the Pacific Islands, and in many areas in Latin America, particularly in
Venezuela and Brazil [38, 39]. This type of malaria infection affects approximately 100–400
million people each year within a population living at risk of 2.5 billion. Interestingly, P. vivax
occurs with an extremely low prevalence throughout much of Africa likely as selective pressure
led to the emergence of the Duffy antigen negativity or red blood cells across African popu‐
lations, particularly in West Africa. However, P. vivax produces substantial morbidity in some
settings at subtropical and temperate latitudes in Asia [11].
P. vivax is responsible for approximately 3.3–30.3% of complications of malaria. In Colombia,
P. vivax is responsible for almost 75% of cases of malaria. In the country, mortality from 130 to
150 cases per year is recorded, because this situation has been considered the disease as a public
health concern with a growing number of complications [10, 11]. P. vivax accounted for 24% of
malaria admissions in all age groups, including 47% of them among infants. In a recent
autopsy‐based report from Brazil, at least four of 17 (23.5%) P. vivax‐associated deaths in Brazil
were attributable to alternative causes at the time of death, including meningitis and yellow
fever, underscoring the ability of this infection to manifest with severe disease often mimicking
other conditions traditionally considered to produce severe clinical manifestations. Mortality
rates in those hospitalized in Indonesian Papua with microscopy‐confirmed P. vivax were
reported as 0.8–1.6%, similar to that of P. falciparum infection (1.6–2.2%)). The adjusted odds
ratio of death from severe anemia in Papua, Indonesia, was 5.9 for those with P. falciparum and
4.4 for those with P. vivax infection [12, 13]. Differences in intensity of transmission might
contribute to the variation in the spectrum of disease severity, as it occurs with falciparum
malaria. Prospective studies from Papua New Guinea conducted to address mortality associ‐
ated with P. vivax infection have shown a mortality rate of 1.6% among hospitalized patients
with P. vivax and of 2.2% among those infected with P. falciparum. These facts illustrate the
similarities in terms of clinical outcomes between both types of human malaria. Further studies
are needed to define P. vivax attributable mortality in endemic areas along with clinical studies
to elucidate the precise pathophysiological and clinical spectrum of disease and from a public
health perspective, the overall magnitude of morbidity and mortality associated with P. vivax
malaria [14].
3. Pathogenesis and disease transmission
The clinical spectrum of disease of P. vivax infection in humans is influenced by many factors:
the parasite, parasite‐host interactions, host factors, and socioeconomic environment in which
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these infections occur [3–5]. For example, low socioeconomic status is associated with higher
risk of developing severe anemia [3]. Studies of specific organs have also shown that the
inflammatory response during infection with P. vivax is of greater magnitude compared with
that seen in P. falciparum infection and also with a parasite biomass similar or greater. Moreover,
cytokine production in P. vivax infections is quantitatively more robust than in P. falciparum
infections with a similar parasite biomass.
P. vivax infections relapse at intervals of 3–4 weeks, and progressive anemia is associated with
recurrent episodes of hemolysis and dyserythropoiesis. In areas with chloroquine resistance,
this is further aggravated by the elimination of delayed parasite infection and risk of reacti‐
vation. The low number of P. vivax parasites indicates that severe anemia may not be produced
by the destruction of infected erythrocytes. This is further evident from the fact that it has been
shown that during P. vivax malaria therapy studies have shown that for each infected eryth‐
rocyte destroyed, 32 uninfected erythrocytes are cleared from the bloodstream. This contrasts
with the loss of only a few infected red blood cells during P. falciparum malaria. The mechanisms
underlying this difference are not known; the proportion of uninfected erythrocytes destroyed
compared to the proportion of extravascular subject (e.g., splenic) pooling is also not known.
Recent studies show an increased fragility microfluidics of infected erythrocytes [14–16].
Pathogenic mechanisms leading to severe symptoms not known exactly, but it have suggested
that a failure of the immune system to control parasite replication or immunopathological
response resulting from excessive inflammation; they are considered as contributing factors
in this response malaria parasites and parasite‐infected red blood cells that activate dendritic
cells activate dendritic. Parasite antigen presenting T helper (Th) 1 cells triggers a pro‐
inflammatory response. The inflammatory response required to eliminate parasites may
produce tissue damage and activation of phagocytes with production of a cytokine cascade
[17].
4. Clinical manifestations
When evaluating patients presenting with a clinical syndrome compatible with malaria, there
are no specific signs or symptoms to assist clinicians in distinguishing infection due to
Plasmodium vivax or plasmodium falciparum; or when there is coinfection by the two species.
Fever in young children may produce seizures. Some individuals progress rapidly to respira‐
tory failure caused by either pulmonary edema or even acute respiratory distress syndrome
(ARDS). Among those with rapid clinical deterioration, we should always consider the
concomitant risk of gram‐negative bacteremias among individuals with either P. vivax or P.
falciparum infection [6, 7]. The main serious manifestation in most series of vivax malaria in
children is severe anemia, defined as hemoglobin < 5 g/dl in children and < 7 g/dl in adults [18].
The pathogenesis of severe malaria is caused by erythrocyte destruction after the invasion of
the parasite by its multiplication and also by morphological deformity of the infected red blood
cell with opsonization and antibody‐dependent lysis of erythrocytes. Indeed, P. vivax‐infected
red blood cells are minimally tacky and are more deformable than P. falciparum erythrocytes
resulting in relatively low red cell sequestration in microvasculature and bone sinuses and the
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passage of a greater proportion of erythrocytes through the reticuloendothelial spleen and
other organs infected [19]. Recurrent episodes of P. vivax infection in highly endemic settings
contribute to a higher risk of severe anemia [20, 21]. Acute respiratory distress syndrome
(ARDS) occurs often in patients with severe P. vivax [22, 23]. Among patients with Plasmodium
vivax infection and presenting with severe clinical manifestating it is important to identify
splenic rupture early. In fact, the incidence of splenic rupture is as high as 24%. Factors leading
to Splenic rupyure include: rapid hyperplasia and parenchymal splenic capsule, forming small
infarcts bleeding, loss connective tissue fibrosis and alterations of primary immunity [6, 10].
Acute kidney injury may occur in both children and adults, and it may result for oliguric renal
failure or even from acute tubular necrosis [24, 25]. Many patients present with multi‐organ
failure and hemodynamic instability requiring vasopressor support and often mechanical
ventilation. Others may develop acute kidney injury from hypovolemic shock secondary to
splenic rupture. All of these potential clinical scenarios should be considered among those
with severe P. vivax infection and particularly among those with rapid clinical deterioration
often requiring intensive care support. In some settings, P. vivax may present with concomitant
bacterial infection including non‐typhoidal salmonellosis or even with enteric fever [26–29].
Finally, patients may also develop seizure disorder or focal neurologic deficits during the
clinical course of P. vivax mono‐infection or when coinfected with P. falciparum [30–32]. Early
recognition and institution of appropriate interventions are crucial to improve overall clinical
outcomes.
5. Diagnosis of severe vivax malaria
Appropriate management of individuals with P. vivax requires confirmation of the diagnosis
by peripheral smear examination. Coinfection with P. falciparum should be entertained in
settings where there are co‐circulations of both Plasmodium species [30]. Early institution of
anti‐parasitic therapy is instrumental. Additionally, ruling out coinfection with bacterial
diseases such as non‐typhoidal salmonellosis or by other enteric‐gram‐negative bacteria is of
utmost clinical relevance. Supportive management in intensive care units should be early
instituted among those with rapid progression to multi‐organ failure and among those with
persistent hypotension despite volume resuscitation or requiring vasopressors due to persis‐
tent hemodynamic instability. Search for potential splenic rupture needs to be considered at
the time of initial presentation, or during the course of illness, among those with rapid clinical
deterioration or those developing severe anemia.
6. Treatment of severe vivax malaria
A summary of core concepts in the management of severe malaria due to P. vivax is depicted
in Table 1. Clinical trials to assess optimal treatment regimens of P. vivax malaria are limited.
At this point in time, in many settings, treatment of vivax malaria consists of chloroquine or
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an artemisinin‐based combination therapy. In those settings where chloroquine resistance
remains low, chloroquine may be used as monotherapy with continuous clinical monitoring.
However, in most settings, an artemisinin‐based combination therapy has become the standard
of care due to the growing recognition of vivax malaria causing severe disease, also due to the
risk of coinfection with P. falciparum (in settings with co‐circulation of both species), and finally
due to the increasing rates of resistance to chloroquine. Some areas consider a universal policy
of treatment with an artemisinin‐based combination therapy (artemether‐lumefantrine) that
is considered the treatment of choice since this drug combination is well tolerated and safe to
pregnant women and children [34]. Additionally, there is an increasing recognition of treat‐
ment failure when using chloroquine or the combination of chloroquine/sulfadoxine‐pyri‐
methamine [35–37].
Clinical category Core concepts
Respiratory failure Protect airway
Provide supplemental oxygen





BIPAP or mechanical ventilation via endotracheal intubation if needed. Patient often requires
PEEP given the possibility of ARDS
Shock Potentially caused by either hypovolemia due to bleeding or septic shock from gram‐negative
bacteremia
Obtain blood cultures; administer broad spectrum antibiotics; correct hemodynamic disturbances
Rule out splenic rupture with abdominal ultrasound or computed tomography
Surgical consultation
Acute renal failure Exclude prerenal causes
Fluid replacement
Hemodialysis or hemofiltration if indicated (i.e., worsening acute kidney injury, acute tubular
necrosis, concomitant severe acidosis, and/or hyperkalemia)
Seizures Protect airway
Benzodiazepines
Other antiseizure medications: Dilantin
Acidosis Exclude or treat hypoglycemia, hypovolemia, and sepsis
If severe, performing hemofiltration or hemodialysis is indicated




Second‐line treatment of complicated malaria
Quinine dihydrochloride combined with either clindamycin (300 mg) or doxycycline (100 mg)
tablets
Presumptive anti‐relapse therapy with primaquine is required to eradicate the liver stage of P.
vivax (hypnozoite), similar to P. ovale in both low‐transmission and high‐transmission settings
Table 1. Clinical spectrum and management of severe/complicated P. vivax malaria.
The spread of drug‐resistant P. vivax to parts of Indonesia, other parts of Southeast Asia, and
South America highlights the urgent need to revisit the spectrum of disease and of the burden
of vivax malaria in order to implement control measures and allocate adequate resources
against this neglected infectious disease [1, 37].
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7. Conclusion
Malaria infection remains as a leading infectious diseases affecting humankind due to its
associated large burden of disease. There is a growing recognition that P. vivax contributes to
a large proportion of this burden. In particular, coinfection of P. vivax and P. falciparum seems
to be synergistic in terms of leading to severe disease, complications, and death among the
most vulnerable populations. The spectrum of disease severity associated with P. vivax
infection ranges from respiratory failure to renal failure. However, the most important marker
of disease severity across borders is produced by hematological abnormalities including severe
anemia and thrombocytopenia. Further research is warranted to address the large epidemio‐
logic burden of disease associated with P. vivax and to identify preventive strategies. From a
clinical perspective, there is a need for further clinical studies to identify strategies to optimize
the clinical management of vivax malaria.
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